CANSINO BIOLOGICS
CanSino Biologics focuses on the R&D, manufacturing, and commercialization of vaccine products for human use. These vaccine products include pneumococcal polysaccharide and conjugate vaccines, and a DTcP-based combo, and other items. It is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine.
CANSINO BIOLOGICS
Industry:
Biotechnology Health Care Medical
Founded:
2009-01-01
Address:
Tianjin, Guangdong, China
Country:
China
Website Url:
http://www.cansinotech.com.cn
Status:
Active
Official Site Inspections
http://www.cansinotech.com.cn Semrush global rank: 1.88 M Semrush visits lastest month: 11.78 K
- Host name: 47.99.161.107
- IP address: 47.99.161.107
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "CanSino Biologics"
康希诺生物
康希诺生物股份公司成立于中国，以在世界范围内提供预防和治疗感染类疾病的解决方案为己任，专注于创新、优质、可及的人用疫苗的研发、生产和商业化，是行业领先的高科技生物制品 …See details»
康希诺生物 - cansinotech.com
Founded in China in 2009, CanSino Biologics Inc. (CanSinoBIO) is an industry-leading biopharmaceutical company, dedicated to providing global solutions for the prevention and …See details»
康希诺生物 - cansinotech.com.cn
George Siber博士在开发疫苗和抗体产品方面有40年的经验，同时还是一名传染病医生。1996年至2007年，Siber博士担任惠氏疫苗公司（现为辉瑞公司）的执行副总裁兼首席科学官，领导研 …See details»
康希诺生物 - cansinotech.com
CanSinoBIO is an industry-leading biopharmaceutical company dedicated to providing global solutions for the prevention and treatment of infectious diseases through research & …See details»
CanSino Biologics - Wikipedia
CanSino Biologics was founded in 2009 in Tianjin by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua. In July 2018, it filed an application to list on the Hong Kong Stock Exchange. It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017. In August 2020, it completed a secondary offering on Shanghai Stock Exchange's STAR marke…See details»
康希诺生物 - cansinotech.com.cn
• 从研发驱动的生物科技公司向成熟的生物医药公司发展; • 持续研发投入，核心研发管线齐头并进; • 探寻多元合作机遇，包括授权、并购及研发管线的海外合作See details»
康希诺 - 维基百科，自由的百科全书
康希诺生物成立于2009年，创始人为宇学峰、毛慧华、朱涛、邱东旭。 [1] 公司于2019年3月28日在香港交易所上市 [2] 。公司在上海证券交易所科创板 首次公开募股的申请已经获得通过 [3] …See details»
康希诺生物 CanSinoBIO - cansinotech.com
2009年，康希诺生物股份公司成立于中国，以在世界范围内提供预防和治疗感染类疾病的解决方案为己任，专注于创新、优质、可及的人用疫苗的研发、生产和商业化，是行业领先的高科技生物制品企业。See details»
CanSino Biologics Inc Company Profile - Overview - GlobalData
Website www.cansinotech.com.cn Telephone 86 22 58213766. No of Employees 2,191. Industry Pharmaceuticals and Healthcare. Ticker Symbol & Exchange 6185 (HKG) Revenue (2023) …See details»
CanSinoBIO - Crunchbase Company Profile & Funding
Tianjin CanSino Biotech Inc. is an emerging biotechnology company dedicated to vaccine research, development and commercialization. We seek to address the pressing unmet …See details»
康希诺生物 - cansinotech.com.cn
• 高级管理层及科学家团队均曾任职于大型全球制药或生物科技公司; • 成熟的新一代疫苗研发及生产技术平台，拥有核心知识产权及专有技术，并在《柳叶刀（The Lancet）》《自 …See details»
CanSino Biologics - Overview, News & Similar companies
Www.cansinotech.com. Revenue $49.3 Million. Industry Manufacturing General Manufacturing . Most Recent Scoops. Apr 25 2022. Project. Aug 3 2020. Initial Public Offering (IPO), a …See details»
康希诺生物 - cansinotech.com
Address: 401-420, 4th Floor, Biomedical Park, 185 South Avenue, TEDA West District, Tianjin, PRC Hong Kong: Room 1901, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay …See details»
康希诺生物
CanSinoBIO is an industry-leading biopharmaceutical company dedicated to providing global solutions for the prevention and treatment of infectious diseases through research & …See details»
康希诺生物 - cansinotech.com
CanSinoBIO complies with laws and regulations such as the Law of the PRC on Pharmaceutical Administration, the Law of the PRC on Vaccine Administration, the Administrative Measures …See details»
康希诺生物 - cansinotech.com.cn
公司研发中心建筑面积超过1.7万平方米，拥有先进实验室资源，包括微生物、分子和细胞生物学、免疫和生物化学及动物实验室，拥有中试基地微生物实验室的生物安全二级实验室，具备开展 …See details»
康希诺生物 - cansinotech.com
Aeras is a non-profit product development organization dedicated to the development of effective tuberculosis (TB) vaccines and biologics to prevent TB across all age groups in an affordable …See details»
康希诺生物 CanSinoBIO - cansinotech.com
世界脊灰日 | 康希诺生物受邀出席who会议 积极展现中国疫苗创新力量See details»
康希诺生物 - cansinotech.com
We persist in developing a full-process quality management system covering R&D, manufacturing and release, and have set clear management requirements for employees and facilities …See details»
康希诺生物 CanSinoBIO - cansinotech.com
This phase IIb clinical study on safety and immunogenicity showed that booster vaccination with CS-2034 can provide broader protection against COVID-19 infections by inducing high-titer …See details»